News

Kamada has already obtained orphan drug designation from both the FDA and the EMEA for aerosolized Alpha-1 Antitrypsin (AAT) for the treatment of congenital emphysema and cystic fibrosis.

The companies will work collaboratively to provide seamless training, installation and customer support services. John Kershaw, president of Sysmex America, said: “We believe our agreement with healthcare veteran

The agreement includes an option to Merck for exclusive worldwide licenses for such peptides – on a peptide by peptide basis – covering the development and commercialization of

Star technology is a production technology that is useful for the production of recombinant human antibodies and proteins. It is said to be effective for production of antibodies

The company intends to grant the underwriters a 30-day option to purchase up to an additional 1.5 million shares of its common stock to cover over-allotments. All of

The subject matter includes several variations of the expression vector system for inducing cells to produce specifically designed single strands of DNA (ssDNA) which may be used in

The expression level of these proteins may help predict how these patients will respond to therapy. A business unit of Genzyme Corporation, Genzyme Genetics’s relationship with Moffitt is

Data from this randomized, multi-center, placebo-controlled withdrawal trial showed that XP13512 (GSK1838262) was generally well-tolerated and that there was a statistically significant difference between the percentage of patients

Under the terms of the agreement, Strativa will have exclusive marketing, sales and distribution rights to Onconase for the treatment of cancer in the US and its territories.